Clinical Trial · NCT05435495

Mechanisms of Resistance to PSMA Radioligand Therapy

Overview

This is a multicenter, correlative study to existing Lutetium based prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) trials and uses.

Sponsor

University of California, San Francisco

Contacts

Thomas Hope, MD (PRINCIPAL_INVESTIGATOR)

Maya Aslam (CONTACT)

maya.aslam@ucsf.edu

(415) 514-8987

ClinicalTrials.gov

NCT05435495

Drug / Compound

PSMA-RLT

Isotope(s):

Target(s):

PSMA

Ligand Class: Small Molecules

Chelator: DOTA

Eligibility

Inclusion

Initiating treatment with Lutetium based PSMA-targeted RLT.
Participants must have a PSMA-avid lesion that is accessible to biopsy. Biopsy of newly emerging radiographic metastases is desired and preferable to the biopsy of previously existing lesions whenever possible. Newly emerging lesions are defined as those that are absent on a previous scan, or those demonstrating unequivocal progression since initiation of the last treatment. Biopsies will be performed according to local institutional standards.

Exclusion

Patients with significant congenital or acquired bleeding disorders (eg von Wildebrand's disease, acquired bleeding factor inhibitors).